摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3(2H)-酮单氢溴酸盐 | 65202-63-3

中文名称
4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3(2H)-酮单氢溴酸盐
中文别名
——
英文名称
3-hydroxy-4,5,6,7,-tetrahydroisoxazolo<5,4-c>-pyridinium bromide
英文别名
3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridinium bromide;4,5,6,7-tetrahydro-isoxazolo[5,4-c]pyridin-3-ol hydrobromide;4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrobromide;gaboxadol hydrobromide;3-hydroxy-4,5,6,7,-tetrahydroisoxazolo[5,4-c]-pyridinium bromide;4,5,6,7-Tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrobromide;4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate;hydrobromide
4,5,6,7-四氢异恶唑并[5,4-c]吡啶-3(2H)-酮单氢溴酸盐化学式
CAS
65202-63-3
化学式
BrH*C6H8N2O2
mdl
——
分子量
221.054
InChiKey
UPVZCNRBPOAABW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    162-163° (dec)

计算性质

  • 辛醇/水分配系数(LogP):
    0.19
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    50.4
  • 氢给体数:
    3
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090

SDS

SDS:9f5294ca5bd23319fd4674fc1340961c
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Heterocyclic compounds
    申请人:H. Lundbeck & Co. A/S
    公开号:US04278676A1
    公开(公告)日:1981-07-14
    The compound Ia ##STR1## has been shown to possess GABA-related activity. The invention relates to Ia and derivatives thereof, covered by the formula ##STR2## in which R" is hydrogen, acetyl or a group of the general formula ##STR3## in which R.sub.5 is C.sub.1-8 alkyl; phenyl; phenyl substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; or phenylalkyl in which the phenyl group may be substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; and salts thereof. Novel intermediates for preparing I are ##STR4## in which Alk is a lower alkyl group and Z is hydrogen or an amino-protecting group; ##STR5## wherein Z is hydrogen or an amino-protecting group, T is a group convertible, by hydrolysis, into an oxy group, and Q is a leaving group which, on reaction with hydroxylamine, forms a hydroxamic acid group; ##STR6## wherein Z and T are as defined above; ##STR7## wherein Z is as defined above, and W is hydrogen or a group removable to yield the free hydroxy group, with the proviso that at least one of Z and W is different from hydrogen.
    化合物Ia##STR1##已被证明具有GABA相关活性。本发明涉及Ia及其衍生物,其公式为##STR2##其中R"为氢,乙酰或一般式##STR3##中的基团,其中R.sub.5为C.sub.1-8烷基;苯基;在4位上用卤素,低烷氧基或低烷基取代的苯基;或苯基烷基,其中苯基在4位上可以用卤素,低烷氧基或低烷基取代;以及其盐。用于制备I的新型中间体为##STR4##其中Alk为低烷基团,Z为氢或氨基保护基;##STR5##其中Z为氢或氨基保护基,T为可通过水解转化为氧基的基团,Q为离去基团,与羟胺反应形成羟肟酸基团;##STR6##其中Z和T的定义如上;##STR7##其中Z的定义如上,W为氢或可去除以获得自由羟基的基团,但至少Z和W中的一个不是氢。
  • Method for manufacture of thip
    申请人:Petersen Hans
    公开号:US20070112198A1
    公开(公告)日:2007-05-17
    The present invention relates to a new method of preparing gaboxadol (THIP), which is useful for treating sleep disorders. In particular a method of preparing THIP comprising reacting a compound of formula (8b) or a salt thereof with an acid, typically a mineral acid, to obtain THIP as an acid addition salt. The present invention also relates to several intermediates.
    本发明涉及一种制备治疗睡眠障碍的Gaboxadol(THIP)的新方法。具体而言,本发明涉及一种制备THIP的方法,包括将式(8b)化合物或其盐与酸(通常是矿酸)反应,以获得THIP的酸加成盐。本发明还涉及几种中间体。
  • Isoxazolo(5,4-c)pyridine derivatives, their preparation and pharmaceutical compositions containing them
    申请人:H.Lundbeck & Co., A/S
    公开号:EP0000338A2
    公开(公告)日:1979-01-24
    Isoxazolo-(5,4-C)-pyridine derivatives of the formula in which R" is hydrogen, acetyl or a group of the formula R5OCO- in which Rs is C1-4-alkyl, phenyl, substituted phenyl; phenylalkyl or substituted phenylalkyl and salts thereof, and intermediates IV, VIII', IX' and V. Compounds (I) may be prepared according to the following reaction scheme: in which Z is hydrogen or a protecting group, T is a group convertible by hydrolysis into an oxo group, Q is a leaving group and W is hydrogen or a group removable to yield the free hydroxy group. Compounds (I) exhibit a y-aminobutyric acid related activity and are useful as active ingredients in pharmaceutical compositions which may, optionally, further contain a minor tranquilizer or a neuroleptic.
    式中的异噁唑-(5,4-C)-吡啶衍生物 其中 R "为氢、乙酰基或式 R5OCO-的基团,其中 Rs 为 C1-4-烷基、苯基、取代苯基;苯基烷基或取代苯基烷基及其盐,以及中间体 IV、VIII'、IX'和 V。 化合物 (I) 可根据以下反应方案制备: 其中 Z 为氢或保护基,T 为可通过水解转化为氧代基团的基团,Q 为离去基团,W 为氢或可去除以产生游离羟基的基团。 化合物(I)具有与 y-氨基丁酸相关的活性,可作为药物组合物中的活性成分,这些药物组合物还可进一步含有轻微的镇静剂或神经安定剂。
  • Isoxazolo(5,4-C)pyridines
    申请人:H.Lundbeck & Co., A/S
    公开号:EP0027279A1
    公开(公告)日:1981-04-22
    The compound wherein Z is hydrogen or an amino-protecting group and W is hydrogen or a group removable to yield the free hydroxy group, with the proviso that at least one of Z and W is different from hydrogen, is a novel intermediate for preparing compound I. The invention covered bytheformula in which R" is hydrogen, acetyl or a group of the general formula VII in which R5 is C1-8 alkyl; phenyl; phenyl substituted in the 4-position with halogen, Ci-4 alkoxy, or C1-4 alkyl; or phenylalkyl in which the phenyl group may be substituted in the 4-position with halogen, lower alkoxy, or lower alkyl. Compound I, in which R" is hydrogen, possesses GABA-related activity.
    其中 Z 是氢或氨基保护基团,W 是氢或可产生游离羟基的基团,但 Z 和 W 中至少有一个不同于氢,该化合物是制备化合物 I 的新型中间体。 本发明包括以下式子,其中 R" 是氢、乙酰基或通式 VII 的基团,其中 R5 是 C1-8 烷基;苯基;在 4 位被卤素、Ci-4 烷氧基或 C1-4 烷基取代的苯基;或苯基烷基,其中苯基可在 4 位被卤素、低级烷氧基或低级烷基取代。 其中 R" 是氢的化合物 I 具有 GABA 相关活性。
  • 3-Piperidinone-4-carboxylic acid derivatives
    申请人:H.Lundbeck & Co., A/S
    公开号:EP0028017A1
    公开(公告)日:1981-05-06
    The compounds in which Alk is a lower alkyl group and Z is hydrogen or an amino-protecting group: wherein Z is hydrogen or an amino-protecting group, T is a group convertible, by hydrolysis, into an oxy group, and Q is a leaving group which, on reaction with hydroxylamine, forms a hydroxamic acid group; wherein Z and T are as defined above, are novel intermediates for preparing compound I. in which R" is hydrogen, acetyl or a group of the general formula VII in which R5 is Ci-8 alkyl; phenyl; phenyl substituted in the 4-position with halogen, C1-4 alkoxy, or Ci-4 alkyl; or phenylalkyl in which the phenyl group may be substituted in the 4-position with halogen, lower alkoxy, or lower alkyl; and salts thereof. The compound I, in which R" is hydrogen, possesses GABA-related activity.
    化合物 其中 Alk 为低级烷基,Z 为氢或氨基保护基团: 其中 Z 是氢或氨基保护基,T 是可通过水解转化为氧基的基团,Q 是与羟胺反应后形成羟肟酸基的离去基团; 其中 Z 和 T 如上定义,是制备化合物 I 的新型中间体。 其中 R "是氢、乙酰基或通式 VII 的基团 其中 R5 是 Ci-8 烷基;苯基;在 4 位被卤素、C1-4 烷氧基或 Ci-4 烷基取代的苯基;或苯基烷基,其中苯基可在 4 位被卤素、低级烷氧基或低级烷基取代;及其盐类。其中 R "为氢的化合物 I 具有 GABA 相关活性。
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰